EXPERIENCE OF NIFURATEL USAGE IN COMPLEX TREATMENT OF CHRONIC SPECIFIC BACTERIAL FIBROUSE AND CALCULOUS PROSTATITIS ASSOCIATED WITH TRICHOMONIASIS AND CANDIDOSIS

Юрий Заседа
{"title":"EXPERIENCE OF NIFURATEL USAGE IN COMPLEX TREATMENT OF CHRONIC SPECIFIC BACTERIAL FIBROUSE AND CALCULOUS PROSTATITIS ASSOCIATED WITH TRICHOMONIASIS AND CANDIDOSIS","authors":"Юрий Заседа","doi":"10.37321/ujmh.2018.01-02","DOIUrl":null,"url":null,"abstract":"The aim of the study was to analyze the effi cacy of the drug “Macmiror” (active substance – nifuratel) in the treatment of chronic specifi c bacterial fi brous and calculous prostatitis associated with trichomoniasis and candidiasis.Materials and methods. The study was conducted on 50 patients of the “Clinic “Men’s Health”, suff ering from chronic specifi c bacterial fi brous and calculous prostatitis (mixed infection: trichomonadial-bacterial-candidiasis associates of various structure). As methods of research, in addition to the standard complex, the following were chosen: IN POUCH TV-test; PCR method; sonographic examination ofthe prostate and spermogram.Results of the study. Patients who completed the study were treated with chronic specifi c bacterial fi brous and calculous prostatitis (N41.1) for 14 days, according to the following therapeutic model: oral administration of nifuratel as part of the “Macmiror” preparation at a total dosage of 1200 mg per day (6 tablets of 200 mg) divided into 3 doses and physiotherapy.Conclusions. A general (in relation to diff erent types and combinations of infectious agents) of the therapeutic model has been established at a level of 71% to 100%. Treatment had absolute (clinical and laboratory) effi cacy against isolated Candida spp.; absolute clinical effi cacy and 71-85% laboratory effi cacy against isolated Trichomonas vaginalis; 92% clinical and 76-84% laboratory effi cacy against the combination of these infectious agents; 92% clinical and 80% laboratory effi cacy against the combination of these infectious agents and non-specifi c bacterial fl ora, as the etiological factors of chronic specifi c bacterial prostatitis.","PeriodicalId":204320,"journal":{"name":"Men’s Health, Gender and Psychosomatic Medicine","volume":"43 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Men’s Health, Gender and Psychosomatic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37321/ujmh.2018.01-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of the study was to analyze the effi cacy of the drug “Macmiror” (active substance – nifuratel) in the treatment of chronic specifi c bacterial fi brous and calculous prostatitis associated with trichomoniasis and candidiasis.Materials and methods. The study was conducted on 50 patients of the “Clinic “Men’s Health”, suff ering from chronic specifi c bacterial fi brous and calculous prostatitis (mixed infection: trichomonadial-bacterial-candidiasis associates of various structure). As methods of research, in addition to the standard complex, the following were chosen: IN POUCH TV-test; PCR method; sonographic examination ofthe prostate and spermogram.Results of the study. Patients who completed the study were treated with chronic specifi c bacterial fi brous and calculous prostatitis (N41.1) for 14 days, according to the following therapeutic model: oral administration of nifuratel as part of the “Macmiror” preparation at a total dosage of 1200 mg per day (6 tablets of 200 mg) divided into 3 doses and physiotherapy.Conclusions. A general (in relation to diff erent types and combinations of infectious agents) of the therapeutic model has been established at a level of 71% to 100%. Treatment had absolute (clinical and laboratory) effi cacy against isolated Candida spp.; absolute clinical effi cacy and 71-85% laboratory effi cacy against isolated Trichomonas vaginalis; 92% clinical and 76-84% laboratory effi cacy against the combination of these infectious agents; 92% clinical and 80% laboratory effi cacy against the combination of these infectious agents and non-specifi c bacterial fl ora, as the etiological factors of chronic specifi c bacterial prostatitis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
硝呋特在滴虫病和念珠菌病合并慢性特异性细菌性纤维性和结石性前列腺炎综合治疗中的应用体会
本研究的目的是分析药物“macmirror”(活性物质-硝呋特)治疗慢性特异性细菌性纤维化和结石性前列腺炎合并滴虫病和念珠菌病的疗效。材料和方法。研究对象为50例“男性健康诊所”慢性特异性细菌性纤维化和结石性前列腺炎患者(混合感染:毛滴虫-细菌-念珠菌病伴发各种结构)。作为研究方法,除标准复合物外,还选择了以下方法:in袋电视试验;PCR方法;前列腺超声检查和精子图。研究结果。完成研究的患者接受慢性特异性细菌性纤维化和结石性前列腺炎(N41.1)治疗14天,治疗模式如下:作为“macmirror”制剂的一部分口服硝呋特,总剂量为每天1200mg(6片,200mg),分3次给药,并进行物理治疗。治疗模式的一般(与不同类型和感染因子的组合有关)已建立在71%至100%的水平上。治疗对分离的念珠菌具有绝对(临床和实验室)疗效;对分离性阴道毛滴虫的绝对临床有效率和71 ~ 85%的实验室有效率;临床有效率为92%,实验室有效率为76-84%;作为慢性特异性细菌性前列腺炎的病因,这些感染因子与非特异性细菌菌群联合治疗的临床疗效为92%,实验室疗效为80%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
НОВІТНІ МЕТОДИ ЛІКУВАННЯ ПОСТКОВІДНОГО ГІПОГОНАДИЗМУ ЯКІСНИЙ ВПЛИВ ІМУНОТЕРАПІЇ АЛЬФА/БЕТА ДЕФЕНЗИНАМИ НА РОЗВИТОК ХІМІО/ПРОМЕНЕВИХ УСКЛАДНЕНЬ ХВОРИХ НА РАК РОТОВОЇ ПОРОЖНИНИ І РОТОГЛОТКИ ОСОБЛИВОСТІ ЗМІН БІОХІМІЧНИХ ПОКАЗНИКІВ У ХВОРИХ З ІНТРАЦЕРЕБРАЛЬНО УСКЛАДНЕНИМ МОЗКОВИМ ІШЕМІЧНИМ ІНСУЛЬТОМ ПІДХОДИ ДО ОЦІНКИ ПРОВОКАТИВНОЇ ПОВЕДІНКИ ТА «ПОШУКУ УВАГИ» У КОНТЕКСТІ ІНТЕРНЕТ-ЗАЛЕЖНОСТІ ВИКОРИСТАННЯ ЕКЗОСОМ ОТРИМАНИХ З МЕЗЕНХІМАЛЬНИХ СТОВБУРОВИХ КЛІТИН У ЛІКУВАННІ ВЕНООКЛЮЗИВНОЇ ЕРЕКТИЛЬНОЇ ДИСФУНКЦІЇ
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1